Goli Samimi

Goli Samimi

UNVERIFIED PROFILE

Are you Goli Samimi?   Register this Author

Register author
Goli Samimi

Goli Samimi

Publications by authors named "Goli Samimi"

Are you Goli Samimi?   Register this Author

49Publications

822Reads

20Profile Views

Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study.

Breast Cancer Res Treat 2019 Feb 9;173(3):719-726. Epub 2018 Nov 9.

Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD, 20850, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-018-5035-0
Publisher Site
http://dx.doi.org/10.1007/s10549-018-5035-0DOI Listing
February 2019

Comparison of 4 commercial kits for the extraction of circulating DNA from plasma.

Cancer Genet 2018 12 6;228-229:143-150. Epub 2018 Mar 6.

Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S22107762173026
Publisher Site
http://dx.doi.org/10.1016/j.cancergen.2018.02.004DOI Listing
December 2018

Population Frequency of Serous Tubal Intraepithelial Carcinoma (STIC) in Clinical Practice Using SEE-Fim Protocol.

JNCI Cancer Spectr 2018 Oct 14;2(4):pky061. Epub 2018 Dec 14.

Division of Epidemiology, Mayo Clinic, Jacksonville, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncics/pky061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649708PMC
October 2018

Ovarian cancer statistics, 2018.

CA Cancer J Clin 2018 07 29;68(4):284-296. Epub 2018 May 29.

Scientific Director, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3322/caac.21456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6621554PMC
July 2018

Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach.

Genet Epidemiol 2018 02 30;42(1):117-122. Epub 2017 Nov 30.

Duke University Medical Center, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gepi.22095
Publisher Site
http://dx.doi.org/10.1002/gepi.22095DOI Listing
February 2018

Ovarian Cancer Prevention in High-risk Women.

Clin Obstet Gynecol 2017 12;60(4):738-757

*Department of Obstetrics and Gynecology, Virginia Commonwealth University, Richmond, Virginia †Johns Hopkins School of Medicine, Kelly Gynecologic Oncology Service, Baltimore, Maryland ‡Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GRF.0000000000000318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920567PMC
December 2017

Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.

Eur J Cancer 2017 12 21;87:182-188. Epub 2017 Nov 21.

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.10.015DOI Listing
December 2017

Traceback: leveraging archived biospecimens to identify mutation carriers.

Oncotarget 2017 Oct 11;8(53):90628-90629. Epub 2017 Oct 11.

Goli Samimi: Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710869PMC
October 2017

Functional prediction of long non-coding RNAs in ovarian cancer-associated fibroblasts indicate a potential role in metastasis.

Sci Rep 2017 09 4;7(1):10374. Epub 2017 Sep 4.

Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-017-10869-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583324PMC
September 2017

Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.

J Clin Oncol 2017 Jul 11;35(20):2329-2337. Epub 2017 Apr 11.

Goli Samimi, Charlisse F. Caga-anan, Michael Dean, Leah E. Mechanic, Lori M. Minasian, and Mark E. Sherman, National Cancer Institute; Lawrence C. Brody, National Human Genome Research Institute, Bethesda, MD; Marcus Q. Bernardini, Stephanie Lheureux, Patricia A. Shaw, Princess Margaret Cancer Centre, Toronto, Ontario; Janice S. Kwon, University of British Columbia; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Ian G. Campbell, Paul A. James, Masataka Takenaka, and David D. Bowtell, Peter MacCallum Cancer Centre; David D. Bowtell, University of Melbourne, Melbourne, Victoria; Georgia Chenevix-Trench, QIMR Berghofer Medical Research Institute, Brisbane, Queensland; Michael Friedlander, The Prince of Wales Hospital; Susan J. Ramus, University of New South Wales; Susan J. Ramus and David D. Bowtell, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; Fergus J. Couch, Mayo Clinic, Rochester, MN; Joanne A. de Hullu and Marline G. Harmsen, Radboud University Medical Center, Nijmegen, the Netherlands; Susan M. Domchek and Ronny Drapkin, University of Pennsylvania, Philadelphia; Phuong L. Mai, Magee-Women's Hospital of the University of Pittsburgh Medical Center, Pittsburgh, PA; Heather Spencer Feigelson, Kaiser Permanente Institute for Health Research, Denver, CO; Mia M. Gaudet, American Cancer Society, Atlanta, GA; Karen Hurley and Mark E. Robson, Memorial Sloan Kettering Cancer Center; Mark E. Robson, Weill Cornell Medical College, New York, NY; Felicitas Lacbawan, Quest Diagnostics Nichols Institute, San Juan Capistrano; Thomas P. Slavin, City of Hope, Duarte, CA; Evan R. Myers, Duke University Medical Center, Durham, NC; Lisa F. Rezende, FORCE: Facing Our Risk of Cancer Empowered, Tampa; Mark E. Sherman, Mayo Clinic, Jacksonville, FL; and Elizabeth M. Swisher, University of Washington Medical Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.3439DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501360PMC
July 2017

Opportunistic salpingectomy: What about the role of the ovary in ovarian cancer?

Cancer 2017 05 23;123(10):1699-1702. Epub 2017 Mar 23.

Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30525DOI Listing
May 2017

Methylated circulating tumor DNA in blood: power in cancer prognosis and response.

Endocr Relat Cancer 2016 Mar 13;23(3):R157-71. Epub 2016 Jan 13.

Garvan Institute of Medical ResearchThe Kinghorn Cancer Centre and St Vincent's Clinical School, 370 Victoria Street, Darlinghurst, Sydeny, New South Wales, AustraliaChris O'Brien LifehouseCamperdown, New South Wales, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-15-0369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737995PMC
March 2016

INC280, an orally available small molecule inhibitor of c-MET, reduces migration and adhesion in ovarian cancer cell models.

Sci Rep 2015 Jul 3;5:11749. Epub 2015 Jul 3.

1] Kinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, NSW, Australia [2] St. Vincent's Clinical School, Faculty of Medicine, UNSW Australia, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep11749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155610PMC
July 2015

Methylation of cell-free circulating DNA in the diagnosis of cancer.

Front Mol Biosci 2015 22;2:13. Epub 2015 Apr 22.

Garvan Institute of Medical Research, The Kinghorn Cancer Centre and St Vincent's Clinical School, University of New South Wales Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmolb.2015.00013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4428375PMC
May 2015

Epigenetic biomarkers in epithelial ovarian cancer.

Cancer Lett 2014 Jan 12;342(2):257-63. Epub 2012 Jan 12.

Cancer Research Program, Garvan Institute of Medical Research, Sydney, Australia.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835120001
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2011.12.036DOI Listing
January 2014

ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer.

Mol Cancer 2014 Jan 6;13. Epub 2014 Jan 6.

Kinghorn Cancer Centre and Cancer Research Program, Garvan Institute of Medical Research, 370 Victoria Street, 2010, Darlinghurst, NSW, Australia.

View Article

Download full-text PDF

Source
http://molecular-cancer.biomedcentral.com/articles/10.1186/1
Publisher Site
http://dx.doi.org/10.1186/1476-4598-13-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895665PMC
January 2014

Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Front Oncol 2013 Dec 4;3:295. Epub 2013 Dec 4.

The Kinghorn Cancer Centre, St Vincent's Clinical School, Garvan Institute of Medical Research , Sydney, NSW , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2013.00295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3849703PMC
December 2013

TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.

Cancer Res 2013 Aug 3;73(16):5016-28. Epub 2013 Jul 3.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-0023DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745588PMC
August 2013

TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.

Cancer Epidemiol Biomarkers Prev 2012 Feb 22;21(2):273-9. Epub 2011 Dec 22.

Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-11-0917DOI Listing
February 2012

Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.

Gynecol Oncol 2010 Oct 8;119(1):114-20. Epub 2010 Jul 8.

Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2010.05.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000175PMC
October 2010

Measures of energy balance and mammographic density in the Nurses' Health Study.

Breast Cancer Res Treat 2008 May 26;109(1):113-22. Epub 2007 Jun 26.

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-007-9631-7DOI Listing
May 2008

Etiology and pathogenesis of epithelial ovarian cancer.

Dis Markers 2007 ;23(5-6):367-76

Department of Obstetrics, Gynecology, and Reproductive Biology, Laboratory of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://downloads.hindawi.com/journals/dm/2007/474320.pdf
Web Search
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851194PMC
http://dx.doi.org/10.1155/2007/474320DOI Listing
March 2008

Biomarkers of mucinous tumors of the ovary.

Dis Markers 2007 ;23(5-6):389-96

Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://downloads.hindawi.com/journals/dm/2007/792356.pdf
Web Search
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851369PMC
http://dx.doi.org/10.1155/2007/792356DOI Listing
March 2008

Cell cycle and related protein.

Dis Markers 2007 ;23(5-6):433-43

Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences 4301 Jones Bridge Road, Bethesda, MD 20814, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850569PMC
http://dx.doi.org/10.1155/2007/464712DOI Listing
March 2008

Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.

Cancer Chemother Pharmacol 2007 Feb 13;59(3):301-12. Epub 2006 Jun 13.

Department of Medicine and Rebecca and John Moores UCSD Cancer Center, # 0819, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0819, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-006-0271-0DOI Listing
February 2007

Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells.

Cancer Chemother Pharmacol 2006 Sep 11;58(3):384-95. Epub 2006 Jan 11.

Department of Medicine, The University of California Medical Center, La Jolla, San Diego, 92093-0819, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0171-8DOI Listing
September 2006

Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters.

Cancer Chemother Pharmacol 2006 Jun 17;57(6):781-8. Epub 2005 Sep 17.

Department of Medicine, The Rebecca and John Moores UCSD Cancer Center, Mail code 0819, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-005-0121-5DOI Listing
June 2006

cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance.

Cancer Chemother Pharmacol 2005 Jan 16;55(1):1-11. Epub 2004 Sep 16.

Department of Medicine and the Cancer Center, University of California, 9500 Gilman Drive, La Jolla, San Diego, 92093-0058, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-004-0819-9DOI Listing
January 2005

Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells.

Clin Cancer Res 2005 Jan;11(2 Pt 1):756-67

Department of Medicine, and the Rebecca and John Moores Cancer Center, University of California-San Diego, San Diego, CA 92093, USA.

View Article

Download full-text PDF

Source
January 2005

The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells.

Mol Pharmacol 2004 Oct 30;66(4):817-23. Epub 2004 Jun 30.

Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla 92093-0058, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.104.001198DOI Listing
October 2004

The role of copper transporters in the development of resistance to Pt drugs.

J Inorg Biochem 2004 Oct;98(10):1607-13

Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, 9500 Gilman Drive, San Diego, La Jolla, CA 92093-0058, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jinorgbio.2004.05.006DOI Listing
October 2004

Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B.

Mol Pharmacol 2004 Jul;66(1):25-32

Department of Medicine, the Rebecca and John Moores University of California San Diego Cancer Center, Biomedical Sciences Graduate Program, University of California, San Diego, La Jolla, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.66.1.25DOI Listing
July 2004

Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells.

Clin Cancer Res 2004 Jul;10(13):4578-88

Department of Medicine, Chemistry and the Cancer Center, University of California, San Diego, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-03-0689DOI Listing
July 2004

Cross-resistance to cisplatin in cells with acquired resistance to copper.

Cancer Chemother Pharmacol 2004 Mar 28;53(3):239-46. Epub 2003 Nov 28.

Department of Medicine 0058, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0058, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-003-0736-3DOI Listing
March 2004

Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients.

Clin Cancer Res 2003 Dec;9(16 Pt 1):5853-9

Department of Medicine and the Cancer Center, University of California-San Diego, La Jolla, California 92093-0058, USA.

View Article

Download full-text PDF

Source
December 2003

The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells.

Mol Pharmacol 2003 Aug;64(2):466-73

Department of Medicine, University of California, San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0058, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/mol.64.2.466DOI Listing
August 2003

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.

Cancer Res 2002 Nov;62(22):6559-65

Department of Medicine and the Cancer Center, University of California, San Diego, La Jolla, California 92093-0058, USA.

View Article

Download full-text PDF

Source
November 2002

Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo.

BMC Cancer 2002 May 31;2:15. Epub 2002 May 31.

Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC115841PMC
May 2002

Using mRNA expression profiling to determine anticancer drug efficacy.

Cytometry 2002 Jan;47(1):66-71

UCSD Cancer Center, University of California at San Diego, La Jolla, California 92037-0058, USA.

View Article

Download full-text PDF

Source
January 2002